AAD
  • Registration
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Topics
  • Daily Coverage
  • Industry Highlights
  • Product Samples
  • Small Exhibit Spotlight
  • Program
Resources
  • Registration
Facebook iconInstagram iconTwitter icon
Jul 07, 2021

Minimizing iatrogenic burden of atopic dermatitis

Treating AD without creating complications.


Co-directors Raj Chovatiya, MD, PhD, FAAD, and Jonathan I. Silverberg, MD, PhD, MPH, FAAD
Co-directors Raj Chovatiya, MD, PhD, FAAD, and Jonathan I. Silverberg, MD, PhD, MPH, FAAD

Current atopic dermatitis (AD) guidelines employ a step-up treatment approach using optimized basic skin care followed by prescription topical and systemic therapy. The sum of these efforts may result in iatrogenic burden, such as morbidity caused by medical treatment, and may actually worsen the patient burden of AD.

“Iatrogenic burden refers to complications or ill effects that result from medical examination or treatment,” said Raj Chovatiya, MD, PhD, FAAD, assistant professor of dermatology at Northwestern Medicine Feinberg School of Medicine, who will be leading the session “Addressing the Iatrogenic Burden of Atopic Dermatitis,” along with co-director Jonathan I. Silverberg, MD, PhD, MPH, FAAD.  “In the case of AD, this iatrogenic burden involves treatment plans that are more burdensome to patients than their signs and symptoms," Dr. Chovatiya said. "Examples include non-evidence-based care or even well-meaning, evidence-based recommendations that are impractical and detrimental to quality of life.”

Dr. Chovatiya pointed to new research that has expanded the armamentarium of treatments as well as our understanding of the immense patient burden associated with AD and its management. “This session will put it all together and introduce practical, everyday strategies that can improve clinical care and make life better for AD patients,” he said.

During this interactive session, the panel will pinpoint key areas that clinicians can minimize this burden. Walking through the current AD treatment paradigm, the speakers will review a therapeutic strategy consisting of step-up, step-down and maintenance approaches in order to reduce treatment burden and improve quality of life in AD.

“AD can be challenging to manage. However, much of the iatrogenic burden associated with AD can be addressed with effective communication and evidence-based shared decision-making,” Dr. Chovatiya said.

CME Credit 1.00



Pearls: AD decision-making

1.   Listen to your patients. This is the only way to understand the impact of AD and its treatments, which can vary significantly between individuals.

2.    Shared decision-making is key. Work together with your patients to craft a plan that is efficacious, safe, feasible, and aligned with individual goals. One-sided plans are rarely sustainable.

3.    Treatment plans can change, and that’s OK! AD has a heterogeneous course and impact, and therapeutic decisions must be as dynamic as the disease itself.

Interesting Stories
Advancing Therapeutic Conversations
Presented by AbbVie
Advancing Therapeutic Conversations
Prurigo Nodularis and Atopic Dermatitis:
Presented by Sanofi and Regeneron Pharmaceuticals, Inc.
Prurigo Nodularis and Atopic Dermatitis:
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Presented by Pfizer Inc.
Beyond the Scalp: Deciphering the Complexities of Alopecia Areata...
Janssen-Sponsored Symposium
Presented by Janssen Biotech, Inc.
Janssen-Sponsored Symposium
Join Us to Learn More About SOTYKTU<sup>TM</sup> (deucravacitinib):
Presented by Bristol Myers Squibb
Join Us to Learn More About SOTYKTUTM (deucravacitinib):
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
Presented by Neutrogena
Residents and Young Physicians: Your Guide to the AAD Annual Meeting
What makes a biosimilar and an Interchangeable biosimilar different?
Presented by Boehringer Ingelheim
What makes a biosimilar and an Interchangeable biosimilar different?
More in Summer Meeting 2021
Peter Lio, MD, FAAD
Summer Meeting 2021
The secrets of minimizing pain
Aug 11, 2021
Lawrence S. Chan, MD, FAAD
Summer Meeting 2021
Biomedical advancements impact dermatologic diagnosis and treatment
Aug 11, 2021
Todd Schlesinger, MD, FAAD
Summer Meeting 2021
Update on managing advanced skin cancer
Aug 11, 2021
Hensin Tsao, MD, PhD, FAAD
Summer Meeting 2021
HPV vax, psoriasis biologics, and caregiver quality of life highlight FiRST session
Aug 11, 2021
07e
Summer Meeting 2021
Summer Meeting packed a welcome punch
Aug 11, 2021
Mario E. Lacouture, MD, FAAD
Summer Meeting 2021
Oncodermatology takes the stage at Fox Lectureship
Aug 06, 2021
Julie Gerberding, MD, MPH
Summer Meeting 2021
COVID-19: A “predictable surprise”
Aug 06, 2021
Aimee Payne, MD, PhD, FAAD
Summer Meeting 2021
Frost Lectureship traces mPV treatment’s path from lab to clinical trial
Aug 06, 2021
2020 Gold Medal Presentation | Professor R. Rox Anderson, MD (left), Lancer Endowed Chair in Dermatology, Harvard Medical School and Director, Wellman Center for Photomedicine at Mass. General Hospital. 2021 Gold Medal Presentation | Dirk Michael Elston, MD, FAAD (right), Medical University of South Carolina.
Summer Meeting 2021
Two physicians honored with AAD Gold Medal awards
Aug 05, 2021
Alina G. Bridges, DO, FAAD
Summer Meeting 2021
New science, technology, and dedication improve dermatopathology
Aug 05, 2021
Sm21 F008 1526e
Summer Meeting 2021
How to have mindful, effective conversations with patients
Aug 05, 2021
Sergey Rekhtman, MD, FAAD, PharmD, MPH, and Sheila Shaigany, MD, FAAD
Summer Meeting 2021
Lessons from COVID-19’s cutaneous manifestations
Aug 05, 2021
AAD
Facebook iconInstagram iconTwitter icon
© Ascend Media All rights reserved. DermWorld Meeting News Central is a publication of the American Academy of Dermatology.